Revolution Medicines, Inc.· RVMD

🇺🇸 US · LargeBroad USNASDAQ

Healthcare Biotechnology Website

Price: $190.95
Day: -3.04%
Mkt Cap: $40.60B
52W Range: $42.18 – $224.31
Volume: 5.93M
Beta: 1.41

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

5D scores: Quality 1.8, Peers 3.5, Valuation 1.0, Analysts 3.5, Holdings 3.8 (out of 5)
Market: $190.95 a share, market cap $40.60B, +322.3% over 12 months
Company: Healthcare · Biotechnology, 883 employees, NASDAQ

Blog

Company Profile

Business fundamentals and company information

Business Description

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.

Key Details

CEO

Mark A. Goldsmith

Employees

883

Headquarters

Redwood City, CA, US

IPO Date

Feb 2020

Exchange

NASDAQ Global Select

Phone

650 481 6801

Healthcare · Biotechnology

SEC filings

10-KFeb 25, 2026 10-QAug 5, 2026 8-KSep 1, 2026

Price Performance

Recent price action and historical returns

Price Performance

$190.95

Historical Returns

Price performance over time

1 Day

-3.04%

5 Day

-6.29%

1 Month

-11.05%

3 Months

+17.15%

6 Months

+99.36%

YTD

+139.74%

1 Year

+322.27%

3 Years

+515.97%

5 Years

+511.43%

10 Years

N/A

Revenue Analysis

How the business makes money, by product and geography

2022 revenue · 1 products

Revenue to Profit Flow · 2022

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A). Operating costs ran past gross profit this year, so the shortfall enters as its own band and the rest of the P&L is listed under the chart.

Learn how to read flow diagrams

Below the line. Nothing flows through an operating loss, so these are shown as figures rather than as flows.

Operating Loss-$258.28M
Other income$9.15M
Tax$420.00K
Net Loss-$248.71M

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

1.8/5

Weak

View Details

Peers

Competitive position

3.5/5

Strong

View Details

Valuation

Model-based valuation (vs. price)

1.0/5

Well above estimate

View Details

Analysts

Wall Street sentiment

3.5/5

Bullish

View Details

Holdings

Smart money flows

3.8/5

Bullish

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.